|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of May 20, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| Restricted Cash | ||||||||||||||||||||
| Restricted Investment | ||||||||||||||||||||
| Mortgages Owned | ||||||||||||||||||||
| Mortgage Servicing Rights, at Fair Value | ||||||||||||||||||||
| Portfolio Loans | ||||||||||||||||||||
| Loans Held for Sale | ||||||||||||||||||||
| Securities | ||||||||||||||||||||
| Right-of-Use (ROU) Leased Asset | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Property and equipment, net of depreciation | ||||||||||||||||||||
| Land - Joint Venture | ||||||||||||||||||||
| Other Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Escrows Payable | ||||||||||||||||||||
| Lease Liability | ||||||||||||||||||||
| Deferred Revenue, net | ||||||||||||||||||||
| Deferred Tax Liability, net | ||||||||||||||||||||
| Contingent Liability, net | ||||||||||||||||||||
| PPP loan payable | ||||||||||||||||||||
| Securities Sold Short | ||||||||||||||||||||
| Line of Credit Payable | ||||||||||||||||||||
| Mortgage Secured Notes Payable | ||||||||||||||||||||
| Warehouse Line of Credit, net | ||||||||||||||||||||
| Notes Payable - Joint Venture | ||||||||||||||||||||
| Other Liabilities and Payables | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Additional Paid-in Capital | ||||||||||||||||||||
| Common Stock, $0.001 par value, 60,000,000 shares authorized 5,000,000 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Preferred stock value | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Non-Controlling Interest | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
